Stock comparison
IDEXX Laboratories
Anbio Biotechnology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
NNNN
Anbio Biotechnology
Market cap
$1.43B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | NNNN | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 58C | IDXX |
| Benjamin Graham | 80A | 87A | NNNN |
| Philip Fisher | 75B | 89A | NNNN |
| Peter Lynch | 71B | 95A | NNNN |
| Joel Greenblatt | 83C | 36D | IDXX |
| Charlie Munger | 87A | 73C | IDXX |
| Terry Smith | 84A | 72C | IDXX |
Side-by-side metrics
| Metric | IDXX | NNNN |
|---|---|---|
| Market cap | $44.06B | $1.43B |
| P/E (TTM) | 39.0x | 171.9x |
| EV/EBIT | 31.6x | 212.9x |
| ROIC (TTM) | 40.66% | 21.48% |
| Gross margin | 62.05% | 87.06% |
| Net margin | 24.63% | 73.75% |
| Revenue CAGR 5y | 7.56% | 18.21% |
| EPS CAGR 5y | 10.79% | 58.42% |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.06Bvs $1.43B+97%
- EV/EBIT31.6xvs 212.9x+85%
- P/E (TTM)39.0xvs 171.9x+77%
- ROIC (TTM)40.66%vs 21.48%+47%
NNNN leads on
- Debt / Equity-vs 0.7x+100%
- EPS CAGR 5y58.42%vs 10.79%+82%
- Net margin73.75%vs 24.63%+67%
- Revenue CAGR 5y18.21%vs 7.56%+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.